Clinical trials: Sialorrhea
Periodontal Diseases, Dental Plaque
Oral Health Literacy Tailored Communication
The purpose of this study to investigate attitude, oral health literacy and psychological factors in order to evaluate if these factors are important for oral health in adults.
- Conditions
- Periodontal Diseases, Dental Plaque, Dental Calculus, Sialorrhea
- Trial name
- NCT01118143
- Testing
- Tailored oral health literacy instruction
- Where
- 2 sites in Norway
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- University of Tromso
Sialorrhea, Parkinson's Disease
Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease
Sialorrhea is a frequently occurring problem with detrimental effect on quality of life in 25% of PD patients. Currently, there is no intervention approved for sialorrhea in Parkinsons and evidence is only available for a 30-day…
- Trial name
- GLYCOPAR (NCT02382198)
- Testing
- Glycopyrrolate
- Where
- 2 sites in Canada
- Volunteers
- 28 people
- Sponsor
- Ottawa Hospital Research Institute
Sialorrhea
Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation
The purpose of this study is to determine if the antisialagogues (anti-salivary agents), Atropine and Glycopyrrolate, are effective in reducing hypersalivation when sedating patients with Ketamine for procedural sedation in the…
- Trial name
- NCT01191398
- Testing
- Atropine (0.01mg/kg), Glycopyrrolate (0.01mg/kg), Normal saline 0.9%
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Craig J. Huang
Clozapine-induced Hypersalivation
Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation
Hypersalivation (sialorrhea or ptyalism) is known as a frequent, disturbing, uncomfortable adverse effect of clozapine therapy, and until now there is not enough effective treatment for this side effect leading to noncompliance.
- Trial name
- CIH (NCT00534573)
- Testing
- Amisulpride, Moclobemide
- Where
- Israel
- Volunteers
- 54 people
- Sponsor
- Beersheva Mental Health Center
Sialorrhea
Clozapine-induced Hypersalivation - Feasibility Trial
A randomised placebo-controlled feasibility study of glycopyrrolate and hyoscine in the treatment of clozapine-induced hypersalivation to assess recruitment and retention rates in a multi-centre trial.
- Trial name
- GOTHIC1 (NCT02613494)
- Testing
- Hyoscine, Glycopyrrolate
- Where
- 2 sites in United Kingdom
- Volunteers
- 29 people
- Sponsor
- Mersey Care NHS Trust
Hypersalivation, Prevention of Drooling
Efficacy of Intravenous Glyco-P® in Patients Undergoing Procedure That Require Anesthesia Service
This observational study was designed to prove clinical efficacy of the well known "glycopyrrolate" which is considered an orphan drug in Thailand.
- Conditions
- Hypersalivation, Prevention of Drooling, Bradycardia, Reversal of Muscle Relaxants
- Trial name
- NCT02102542
- Where
- Thailand
- Volunteers
- 65 people
- Sponsor
- Mahidol University
Sialorrhea
A Retrospective Chart Abstraction to Investigate the Prevalence of Chronic Sialorrhea, and the Real-world Use of incobotulinumtoxinA Injections in Male and Female Participants Aged 18 Years and Older With Chronic Sialorrhea
A retrospective, multicenter chart abstraction to investigate the prevalence of chronic sialorrhea, and the real-world use of incobotulinumtoxinA injections in male and female participants aged 18 years and older with chronic…
- Trial name
- NCT07881497
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- Medstar Health Research Institute
Chronic Troublesome Sialorrhea, Parkinson's Disease
Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions
The objective of this study is to investigate the efficacy and safety of two different dose levels of NT 201 (75 U or 100 U per cycle), compared with placebo, in reducing the salivary flow rate, and the severity and frequency of…
- Conditions
- Chronic Troublesome Sialorrhea, Parkinson's Disease, Post-stroke, Traumatic Brain Injury
- Trial name
- SIAXI (NCT02091739)
- Testing
- IncobotulinumtoxinA (100 Units), IncobotulinumtoxinA (75 Units)
- Where
- 31 sites in Germany, Poland
- Volunteers
- 184 people
- Sponsor
- Merz Pharmaceuticals GmbH
Sialorrhea
Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
This study is being conducted this study to determine whether injections of Xeomin®, a type of botulinum toxin into the glands that produce saliva (one pair just below and in front of the ear and the other just under the jaw…
- Trial name
- NCT01653132
- Testing
- Incobotulinum Toxin A
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Beth Israel Deaconess Medical Center
Chronic Troublesome Sialorrhea, Cerebral Palsy
Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
The objective of this study is to investigate the efficacy and safety of NT 201 compared with placebo for the treatment of chronic troublesome sialorrhea associated with neurological disorders (e.g.
- Conditions
- Chronic Troublesome Sialorrhea, Cerebral Palsy, Stroke, Traumatic Brain Injury
- Trial name
- SIPEXI (NCT02270736)
- Testing
- NT 201
- Where
- 31 sites in Georgia, Hungary and 4 more
- Volunteers
- 256 people
- Sponsor
- Merz Pharmaceuticals GmbH
Transcutaneous Vagal Nerve Stimulation (tVNS), Parkinson Disease (PD)
Effects of Transcutaneous Vagus Nerve Stimulation in Parkinson´s Disease
This study aims to determine whether electrical stimulation of the ear, when combined with physical and speech therapy, can improve symptoms in subjects diagnosed with Parkinson´s disease, by comparing two different application…
- Trial name
- tVNS_PD (NCT07588191)
- Testing
- Transcutaneous Electrical Nerve Stimulation (TENS) of Vagus Nerve, Conventional Physical therapy, Conventional Speech Therapy
- Where
- Spain
- Volunteers
- 46 people
- Sponsor
- Universidade da Coruña
Sialorrhea (Excessive Drooling)
Study of the Safety and Efficacy of Tropicamide Thin Films to Reduce Hypersalivation in Parkinson's Patients
To study the safety and efficacy of tropicamide 1 mg intra-oral slow dissolving muco-adhesive thin films compared to placebo to reduce hypersalivation in PD patients manifesting sialorrhea complaints.
- Trial name
- NCT01844648
- Testing
- NH004 tropicamide
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- NeuroHealing Pharmaceuticals Inc.
Salivation
Acute Salivary Flow Rate Response to Transcutaneous Electrical Nerve Stimulation Versus Electro-acupuncture
Between available therapies for dry mouth is electrostimulation. Using an extra-oral device like TENS - which result in a statistically significant - increases the quantity of whole salivary flow rate production in xerostomia…
- Trial name
- NCT04211324
- Testing
- TENS, electro-acupuncture
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Cairo University
Schizophrenia, Clozapine
The Treatment of 2 Chinese Medicines in Clozapine-induced Hypersalivation in Schizophrenia
The goal of this research is hoping to combine traditional Chinese medicine medication and find out how to solve clozapine-induced hypersalivation, also reduce side-effect, medication compliance, improving life quality, improving…
- Conditions
- Schizophrenia, Clozapine, Hypersalivation, Traditional Chinese Medicine
- Trial name
- NCT01045720
- Testing
- Suo Quan Wan, Wu Lin San
- Where
- Taiwan
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Taichung Veterans General Hospital
Amyotrophic Lateral Sclerosis, Sialorrhea
Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to determine the safety and efficacy of Myobloc in ALS patients who are having excessive drooling. The primary goal of the study is to determine if the patient perceives a benefit from the Myobloc in…
- Trial name
- NCT00125203
- Testing
- Botulinum toxin type B (Myobloc), Injection of salivary glands
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Main Heading (Descriptor) Terms
Mid-and Long-term Efficacy of Ergot Alkaloids in the Treatment of Salivation in Patients With Parkinson's Disease.
Parkinson's disease is the second most common neurodegenerative disease after Alzheimer's disease, the incidence of population over 60 years old in China is 1.37%, Parkinson's disease is often accompanied by various non-motor…
- Trial name
- NCT06035913
- Testing
- Dihydroergot mesylate
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Drooling
A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients
To determine safety, tolerability and preliminary efficacy of intraglandular injections of MYOBLOC for the treatment of sialorrhea in Parkinsons' Disease patients
- Trial name
- NCT00515437
- Testing
- Botulinum Toxin Type B (Myobloc)
- Where
- 18 sites in United States
- Volunteers
- 54 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Autism Spectrum Disorder, Chewing Problem
Oral Structural and Functional Problems in Children With Autism
This study aims to examine oral structural and functional problems in children with autism.
- Conditions
- Autism Spectrum Disorder, Chewing Problem, Drooling
- Trial name
- NCT06355141
- Testing
- oral assessment
- Volunteers
- 90 people
- Sponsor
- Hacettepe University
Weight Gain, Sialorrhea
FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey
AZUR Pharma has received several reports from practicing psychiatrists prescribing FazaClo showing that FazaClo patients start losing body weight instead of keep gaining it, after being switched from other clozapine products or…
- Trial name
- FOCUS (NCT00683891)
- Testing
- FazaClo (clozapine, USP) ODT
- Where
- 2 sites in United States
- Sponsor
- Azur Pharma, Inc
Sialorrhea
Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
This study will evaluate the efficacy and safety of MYOBLOC in the treatment of Sialorrhea (drooling), which can be a symptom of many disease conditions. MYOBLOC will be injected directly into the salivary glands.
- Trial name
- MYSTICOL (NCT01994109)
- Testing
- MYOBLOC
- Where
- 34 sites in United States, Russia and 1 more
- Volunteers
- 187 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC